<?xml version="1.0" encoding="UTF-8"?>
<p id="p0165">To also stimulate the uptake of innovative medical products in emerging markets, where no expedited pathways are already available, regulatory agencies can consider the use of such pathways beyond COVID-19 and for a wider gamut of products or services, such as in the case of emergency situations or in allowing for an expedited approval of medical products for serious, life-threatening diseases. Nonetheless, any new expedited pathway introduced need to be carefully crafted, and experiences from other regulators that have implemented such pathways can be further leveraged.
 <xref rid="bib56" ref-type="bibr">
  <sup>55</sup>
 </xref>
</p>
